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Environmental factors account for 75% of the risk of
developing multiple sclerosis (MS). Numerous infec-
tions have been suspected as environmental disease
triggers, but none of them has consistently been
incriminated, and it is unclear how so many different
infections may play a role. We show that a microbial
peptide, common to several major classes of
bacteria, can induce MS-like disease in humanized
mice by crossreacting with a T cell receptor (TCR)
that also recognizes a peptide from myelin basic
protein, a candidate MS autoantigen. Structural
analysis demonstrates this crossreactivity is due to
structural mimicry of a binding hotspot shared by
self andmicrobial antigens, rather than to degenerate
TCR recognition. Biophysical studies reveal that the
autoreactive TCR binding affinity is markedly lower
for the microbial (mimicry) peptide than for the auto-
antigenic peptide. Thus, these data suggest
a possible explanation for the difficulty in incrimi-
nating individual infections in the development ofMS.
INTRODUCTION
Multiple sclerosis (MS) is an incurable inflammatory and degen-
erative disease of the central nervous system (CNS), affecting
approximately 1–2 million people worldwide (Sospedra and
Martin, 2005). Susceptibility to MS is jointly determined by
genetic and environmental factors. Identifying these factors
and their interplay is important in understanding the disease
mechanisms, which can be targeted by drugs.
Progress has beenmade in understanding which genes confer
risk of MS. In Northern European Caucasoid populations, MS is348 Immunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc.associated with three different MHC class II alleles that belong
to the HLA-DR2 (DR2) haplotype: DRB1*1501 and DRB5*0101,
which encode b chains of the DR2b and DR2a molecules,
respectively; and DQB1*0602, which encodes the b chain of
the HLA-DQ6.2 molecule (Olerup and Hillert, 1991). Of these,
three recent studies have implicated the HLA-DR, rather than
the HLA-DQ, loci as conferring the strongest susceptibility to
MS (Gregersen et al., 2006; Lincoln et al., 2005; Oksenberg
et al., 2004). This association is supported by mechanistic
studies strongly implicating HLA-DR-restricted T cell-mediated
autoimmunity to myelin antigens, including myelin basic protein
(MBP), proteolipid protein (PLP), and myelin oligodendrocyte
glycoprotein, in the pathogenesis of MS (Sospedra and Martin,
2005). MBP has received particular attention, because MBP-
specific CD4+ T cell receptors (TCRs) have been found in the
brains of MS patients (Oksenberg et al., 1990) and an immuno-
dominant T cell epitope of MBP (residues 85–99), complexed
with DR2b, is presented by antigen-presenting cells in MS
lesions (Krogsgaard et al., 2000). Moreover, humanized mice,
transgenic for DR2b and an MS patient-derived MBP 85–99-
DR2b-specific TCR (Ob), developMS-like disease, experimental
autoimmune encephalomyelitis (EAE), either spontaneously (in
Rag2/mice) or after immunization with theMBP 85–99 peptide
(in Rag+/+ mice) (Madsen et al., 1999; Gregersen et al., 2006).
Structural and biophysical studies have also added to our
understanding of how MHC class II molecules may predispose
one to MS. Structural study of the autoreactive Ob TCR revealed
that it binds in a distinctive position toward the N-terminal region
of the MBP 85–99 peptide presented by DR2b (Hahn et al.,
2005). This unconventional binding mode has been suggested
to play a role in allowing theOb TCR to escape negative selection
during thymic maturation (Hahn et al., 2005). A second autoreac-
tive TCR (3A6) has subsequently been reported to contact the
MBP 85–99-DR2a complex at the N-terminal region of the
peptide, but to a much lesser extent than that of the Ob TCR
(Li et al., 2005a). Combined peptide-epitope mutagenesis,
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increasingly argue against any nonstandard binding footprint on
MBP-DR2b and show, rather, that low-affinity binding to self-
peptide-MHC is a common denominator (our unpublished
results and those of Li et al., 2005a). This supports a mechanism
whereby self-reactive TCRs require an affinity that is low enough
to escape negative selection in the thymus but is above aminimal
threshold for activation in the periphery (Hogquist et al., 2005).
Taken altogether, cellular, mouse model, and molecular studies
have begun to provide substantial insight into the mechanisms
by which the largest genetic risk factor in MS, MHC class II,
confers susceptibility to the disease.
In contrast, little is known about the identity of the environ-
mental factors in MS (which account for 75% of the disease
risk), their mechanism(s) of action, and their interplay with
susceptibility genes. Numerous microbial infections are sus-
pected to act as environmental triggers, because they are often
associated with MS relapses, but none of them has consistently
been incriminated (Sibley et al., 1985; Buljevac et al., 2002;
Correale et al., 2006). It is unclear both how so many different
infections may play a role in the pathogenesis of MS and what
mechanism(s) allow them to do so. According to one hypothesis,
that of molecular mimicry, some T cells that respond to an
epitope derived from a single infectious agent can crossreact
with a self antigen that may share sequence or structural
homology with the original microbial peptide (Oldstone, 1987).
However, it has been difficult to establish a convincing role for
T cell epitope mimicry in human autoimmune disease because
of the dearth of well-documented examples (Benoist andMathis,
2001). Thus, in the absence of any robust mechanistic model
explaining how environmental factors confer the major propor-
tion of the risk, much of the pathway to autoimmune disease
remains obscure.
We have exploited the well-documented, MS-relevant, MBP
(85-99)-DR2b-Ob TCR system to uncover and validate a mecha-
nism by which a broad range of different infections may mediate
MS as a result of the structural homology of a very limited
number of residues in the T cell epitope. By combining
disease-induction studies and neuropathological studies in
a humanized model for MS, with sequence analysis, as well as
structural and biophysical study, we addressed a series of inter-
connected questions: How might numerous different pathogens
trigger the same disease pathway? To what extent does molec-
ular mimicry, as opposed to molecular promiscuity, play a role in
TCR crossreactivity? What binding affinities are characteristic of
the crossreactive interactions, and are such interactions capable
of inducing disease? Our answers to these questions combine to
provide a proof of principle for amechanism of action that can be
shared by multiple microbes. This model mechanism for the
action of a diverse group of environmental risk factors has
implications not only for MS but also for any T cell-mediated
autoimmune disease.
RESULTS
Common Microbial Peptides Trigger Autoimmune
Disease in Humanized Mice
In vitro studies have shown that the Ob TCR also reacts with five
DR2b-binding microbial peptides that share limited sequenceidentity with each other or with MBP 85–99 (Hausmann et al.,
1999). These peptides were originally assigned to known
proteins or open reading frames (ORFs) within the genomes
of Mycobacterium avium (M. avium), Escherichia coli (E. coli),
Haemophilus influenzae (H. influenzae), Bacillus subtilis
(B. subtilis), Mycobacterium tuberculosis (M. tuberculosis), and
Staphylococcus aureus (S. aureus) (Hausmann et al., 1999). A
sequence-identity search against all available annotated
genomes, with the use of Blast through the ExPASy server at
http://expasy.org/tools/blast/, yielded a comprehensive list of
organisms that contain these peptides (Table S1, available
online). The originally unidentified ORF peptide from E. coli and
H. influenzae is in fact part of a highly conserved guanosine
triphosphate (GTP)-binding bacterial protein, engA, which is
found in at least three orders of the Gammaproteobacteriae
class: Aeromonadales, Pasteurellales, and Enterobacteriales.
We have demonstrated that this engA epitope is naturally
processed and presented by DR2b molecules to Ob T cells
(Figure S1).
We selected the E. coli, M. avium, and MBP peptides for
study because they stimulate the Ob T cells in vitro with low,
intermediate, or high potency, respectively. Binding affinities for
these peptides to purified HLA-DR2b molecules have previously
been quantitated, and M. avium and M. tuberculosis peptides
competed for MBP peptide binding at the lowest peptide
concentrations, followed by the E. coli and H. influenzae
peptide (Hausmann et al., 1999). However, the overall difference
between the peptide binding affinities was less than 2.5-fold. We
compared the ability of these peptides to induceMS-like disease
in humanized Ob TCR-DR2b transgenic mice. Both microbial
peptides evokedaggravateddisease in everymouse; thedisease
evoked with the M. avium peptide was almost as severe as that
evoked with the MBP peptide but was significantly milder than
that evoked with the E. coli peptide. By contrast, adjuvant alone
induced onlymild disease and in only half of the injected animals;
furthermore, its onset was significantly delayed (Table 1). We
excluded contributions from the broad repertoire of endogenous
(murine) TCRchains, by confirming the encephalitogenicity of the
E. coli peptide in similar transgenic mice bred onto a Rag2/
background (with no endogenous TCR chains [p = 0.009]).
We investigated brains and spinal cords from the immunized
mice for histopathological changes. The brains of the Ob TCR-
DR2b mice showed similar inflammatory infiltration by T cells
and macrophages, extending from perivascular areas into the
adjacent brain parenchyma, regardless of the peptide used for
immunization (Figures 1A–1H). In addition, we searched for
axon loss, axon damage, and myelin loss. We found axon loss
in the spinal cord (Figures 1I–1L), a characteristic that is related
to irreversible disability in MS (Kornek et al., 2000). The spinal
cord also showed an inflammatory infiltrate that was notably
greater after immunization with MBP than after that with
M. avium or, especially, the E. coli peptides, after which it was
more focal (Figure S2, Table S2). Myelin loss was seen only close
to perivascular regions where we also found macrophages with
engulfed proteolipid protein fragments (Figure 2); by contrast,
axon damage was more widespread in the inflamed lesions
(Figure 2). The extent of myelin loss and axonal damage was
proportional to the degree of inflammation (Figure S3). Evidently,
the crossreactive Ob TCR is indeed fully capable of initiatingImmunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc. 349
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Trans Genes Peptide Disease Frequency P Value
Mean Maximum
Severity Scorea p Value
Median Day of
Onsetb p Value
Ob-DR2b no peptide 5/9 - 1.80 (1.10) - 24.0 (17.0 – 54.0) -
Ob-DR2b MBP 84-102 13/13 0.017c 3.92 (0.86) <0.001c 14.0 (7.3 – 16.0) 0.002c
Ob-DR2b M. avium 11/11 0.026c 3.46 (1.29) 0.027c 13.0 (10.2 – 15.2) 0.002c
Ob-DR2b E. coli 12/12 0.021c 3.08 (1.00) 0.033c 0.035d 15.0 (12.0 – 25.7) 0.018c
0/9 nontransgenic, 0/10 Ob, and 2/17 DR2b single-transgenic mice developed mild disease.
a Numbers shown in parentheses correspond to standard deviations.
bNumbers shown in parentheses correspond to a confidence interval of 0.05–0.95.
c versus Ob-DR2b (no peptide).
dOb-DR2b (M. avium) versus Ob-DR2b (E. coli).MS-like disease after being stimulated with microbial peptides
by the DR2b molecule.
A Structural Hotspot for Molecular Mimicry
To identify the molecular features providing the basis for this
crossreactivity, we determined the crystal structure of a soluble
Ob TCR and E. coli peptide-DR2b (E. coli-DR2b) complex.
Previously, the structure of the Ob TCR in the complex with
MBP 85–99 presented by DR2b was solved to 3.5 A˚ resolution
(Hahn et al., 2005). The Ob TCR E.coli-DR2b was solved by
molecular replacement, with the use of a complete data set
(collected from multiple sites on a single crystal), to 3.15 A˚
resolution and refined to Rwork 23.6 (Rfree 25.9) (Table 2).The Ob TCR and E. coli-DR2b have structures typical of TCR
and MHC class II molecules, respectively (reviewed in Jones
et al., 2006; Rudolph et al., 2006) (Figure 3, Figure S4). The
E. coli peptide lies extended in the a1 and b1 presentation groove
and loops over the edge of a1 N-terminally. It binds to DR2b
through a combination of hydrophobic and charged interactions.
PositionsP1,P3,P4, andP7are all cushionedwithin cavities lined
with hydrophobic residues. In DR2b, the P1 and P4 pockets are
the key binding sites for peptide side chains, imposing a hydro-
phobic anchor motif (Smith et al., 1998) that the E. coli peptide
fulfils with P1-Val and P4-Ile (nomenclature as defined in
Figure 3B; Figure S5). The P6-Ala and P9-Gly anchor residues
are not optimal. The backbone of the bound peptide is lockedFigure 1. Inflammation and Axon Loss in
the Brain and Spinal Cord of Immunized
Ob TCR -DR2b Mice
(A–D) T cell infiltration (stained with anti-CD3)
and (E–H) macrophage infiltration (stained
with anti-Mac3) in equivalent regions of the
cerebellar white matter of (A and E) Ob-DR2b
MBP-immunized mice, (B and F) Ob-DR2b
M. avium-immunized mice, and (C and G) Ob-
DR2b E. coli-immunized mice. Adjuvant alone
immunization used as negative control (D and H,
respectively). (A–C) and (E–G) Increased inflamma-
tion was observed, at similar levels, in the brains of
Ob-DR2b-immunizedmice. (I–L) Axonal loss in the
spinal cord of antigen-immunized mice, analyzed
in transverse sections of the dorsal columns. (I)
MBP-immunized Ob-DR2b mice, (J) M. avium-
immunized Ob-DR2b mice, and (K) E. coli-
immunized Ob-DR2b mice (adjuvant alone shown
in [L]). Axons are shown in transverse sections as
brown dots of varying size. The sections were
stained with a neurofilament antibody. Magnifica-
tion: (A–H) 403 and (I–L) 4003. Three mice were
analyzed in each group of immunized mice.
350 Immunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc.
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but two residues of the total extend of the peptide.
For the crystal structure of MBP-DR2b in isolation, suboptimal
binding was implicated in the somewhat elevated positioning of
the C-terminal half (P5-P10) of the MBP peptide (Smith et al.,
1998). However, this distinctive peptide position is not recapitu-
lated either in our structure of the Ob TCR-E. coli-DR2b complex
or in the Ob TCR-MBP-DR2b complex (Hahn et al., 2005). This
suggests that Ob TCR binding is accompanied by conforma-
tional adjustments of the peptide-DR2b.
With the exception of P1-Val, P2-His, and P3-Phe, the
sequences of the E. coli and MBP peptides are very different
(Figure 3C, Figure S4, and Figure S6). These differences can
have an impact on TCR recognition directly, through side-chain
interactions, or indirectly, through changes in the positioning of
the peptide main chain or DR2b residues. Structural superposi-
tion of the peptide-DR2b molecules from the current and previ-
ously reported Ob TCR-peptide-MHC complexes reveals that
the E. coli and MBP peptide main chains are positioned identi-
cally for residues P1 to P2 and have only minor differences,
up to and including the P9 anchor position (0.5–0.7 A˚ rmsd for
equivalent pairs of Ca atoms; Figure 3C and Figure S6). As
a result, the peptide-residue side chains of that protrude from
the groove are very similarly positioned in the two complexes;
the P2-His and P3-Phe side chains, common to both peptides,
superimpose exactly (Figure 3C, Figure S5). This ‘‘hotspot’’ of
structural conservation between the E. coli-DR2b and MBP-
DR2b surfaces lies at the heart of their respective interfaces
with the Ob TCR (Figure S7).
As previously reported for the Ob TCR MBP-DR2b complex
(Hahn et al., 2005), the binding footprint of the Ob TCR on
E. coli-DR2b is an outlier among current structures of TCR-
peptide-MHCcomplexes (Rudolph et al., 2006); it is offset toward
the N terminus of the peptide (Figure 3D, Figure S8). Both
complexes show direct interactions between the Ob TCR and
Figure 2. Inflammation, Demyelination, and
Acute Nerve Damage in the Cerebellum of
an Ob TCR-DR2b Mouse Immunized with
an E. coli Peptide
(A and B) Myelinated fibers are stained brown
(anti-PLP antibody) and nuclei are stained blue
(hematoxylin staining). The arrow points to cell
infiltration, forming a perivascular cuff in which
myelin has been destroyed (A). Adjuvant-only
control is included (B).
(C and D) The same region as in (A) is shown, with
brown spots depicting accumulation of beta-
amyloid precursor protein (C). Adjuvant-only
control is included in (D).
Magnification is shown at 1003.
the side chains of peptide residues P1,
P2, P3, and P5 (Figure 3E; Figure S4;
Table S3). The ‘‘dome’’ composed of the
two CDR3 loops, identified in an earlier
report (Hahn et al., 2005), retains its Ca
architecture with no deviations. The
phenyl ring of Tyr-98 in the CDR3a loop
stacks against the aliphatic portion of
the arginine side chain at P1 in E. coli-DR2b, matching the
hydrophobic character of the interaction it makes with P1-Val
in MBP-DR2b, whereas the CDR3b loop interacts identically
with P2-His andP3-Phe in both complexes. The nonconservative
sequence difference at P5 (serine and arginine in the MBP and
E. coli peptides, respectively) results in a switch from
hydrophobic to polar interaction with the CDR3b loop (in Ob
TCR-MBP-DR2b and Ob TCR-E. coli-DR2b, respectively)
(Figure S3, Table S3). The only marked change in DR2b structure
between the two complexes is a shift of up to 1.4 A˚ in main chain
atoms for the midsection of the b1 helix (B63–B76) (Figure 3D,
Figure S9), a region outside the Ob TCR binding footprint.
Despite the distinctive offset position of the Ob TCR footprint
on the DR2b binding groove (the TCR exhibits a counterclock-
wise rotation relative to the peptide-MHC with an orientation
angle of 100, as opposed to 50–80 for other TCR-
peptide-MHC complexes), the overall surface area buried
(1133 A˚2 and 1176 A˚2 on E. coli-DR2b and MBP-DR2b, respec-
tively) remains within (albeit at the lower end of) the standard
range observed for TCR-peptide-MHC interactions (Rudolph
et al., 2006) (Table S4). In particular, the extent of interactions
with the peptide is similar, if not greater, than that reported for
other TCR recognition events of both MHC class I and class II
molecules (Rudolph et al., 2006) (for example, 457 A˚2 and 453
A˚2 of peptide surface is buried in the Ob TCR-E. coli-DR2b
[Hahn et al., 2005] and HA1.7 TCR-hemagglutinin-DR4
complexes [Hennecke and Wiley, 2002], respectively). The rela-
tive TCR-peptide-MHC geometry does differ slightly between
the two complexes with the orientation of Ob TCR changed by
a twist of some 3 about its long axis. This change is insufficient
for impact on the conserved interactions at the core of the inter-
face but may reflect some adjustment to differences in the
periphery of the binding footprint. In order to assess to what
extent these differences might modulate Ob TCR recognition,
we analyzed the binding properties of this TCR-pMHC system.
Immunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc. 351
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Molecular Mimicry in Multiple SclerosisTable 2. Crystallization, Data Collection, Phasing, Refinement
Statistics, and Model Quality
Crystallization
Protein 12.5 mg/ml in 20 mM BisTris pH 6.3,
150 mM NaCl
Reservoir 0.2 M LiSO4, 0.8 M K2HPO4,
1.2 M NaH2PO4, 0.1 M CAPS
pH 10.5, 8 % 1,1,1,3,3,
3-hexafluoro-2-propanol
Cryoprotection Perfluoropolyether PFO-X125/03
(Lancaster Synthesis)
Data Collection
Beamline ID23.2 ESRF Grenoble, France
Detector MAR Mosaic 225
Software Denzo/Scalepack
Space group P212121
Unit cell dimensions (A˚, ) a = 109.5, b = 129.8, c = 180.3,
a = b = g = 90
Wavelength, A˚ 0.8726
Resolution, A˚a 30.0-3.15 (3.26–3.15)
Completeness, %a 100 (100)
Unique dataa 45 361 (4 466)
Redundancya 16.9 (16.6)
I/sIa 10.3 (2.1)
Rmerge
a,b 22.9 (>100)
Phasing
Method Molecular replacement
Software AMoRe
Model used 1YMM.pdb
Refinement Statistics (jFj > 0 s)
Software REFMAC
NCS restraints tight main chain/medium side chain
Resolution, A˚ 30.0-3.15
Completeness 99.70
No. of unique reflections 42 965
Rfact, %
c 23.6
Rfree, %
c,d 25.9
Rmsd bond lengths, A˚e 0.007 (0.022)
Rmsd bond angles, e 0.989 (1.932)
Rmsd chiral volumes, A˚3e 0.071 (0.200)
Rmsd main chain bond, A˚2 1.078 (3.000)
Rmsd side chain bond, A˚2 1.984 (4.000)
Average main chain B factor, A˚2 63.4
Average side chain B factor, A˚2 64.3
NCS-related rmsd
main-/side-chain positional, A˚e 0.03 (0.05) / 0.35 (0.50)
main-/side-chain thermal, A˚2e 0.04 (0.50) / 0.32 (2.00)
Model Quality (Ramachandran Analysis)
Software PROCHECK
Total number of residues 1 640
Favoured, % 87.1
Allowed, % 12.1
Disallowed % 0.8352 Immunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc.Low-Affinity TCR Binding to Microbial Peptides
Presented by DR2b
Usingsurfaceplasmon resonanceanalysis,we found thatObTCR
binds the MBP-DR2b complex with an affinity of Kd  47 mM
(Figure S10), which is at the low end of reported affinities for
functional syngeneic TCR-pMHC interactions (van der Merwe
and Davis, 2003). The affinity of Ob TCR for the five microbial
peptide-DR2b complexes was even weaker; for the E. coli and
M. avium peptides that induce disease in the mice, the Kd values
were 300and 450mM, respectively, whereas for theB. subtilis and
M. tuberculosis peptides, they were 220 mMand 670 mM, respec-
tively (Figures 4A–4F). Analysis of the binding kinetics for these
two complexes indicates that these exceptionally low affinities
were the result of a combination of faster koff values (0.3 s1)
and slower kon values (700 M1.s1) (Figure 4E, Table 3). The
koff values were at the fast end of the range previously reported
for syngeneic agonist TCR-peptide-MHC interactions (Boulter
et al., 2007; van derMerwe andDavis, 2003) (0.02 < koff < 0.9 s
1),
whereas the kon values were significantly slower (3000 > kon >
200,000 mol1.s1) (van der Merwe and Davis, 2003).
Analysis of the thermodynamic properties of these interactions
indicated that, as with other TCR-peptide-MHC interactions, Ob
TCRbindingwas characterized by favorable changes in enthalpy
(DH) and unfavorable changes in entropy (TDS) (Figure 4F,
Table 3). Notably, Ob TCR binding to the E. coli and M. avium
peptide-DR2b complexes was characterized by highly unfavor-
able entropic changes, highly favorable enthalpic changes, and
unusually large changes in heat capacity (DCp values = 1.5
and 2.0 kcal.mol1.K1, respectively). Taken together with
the unusually slow kon, these thermodynamic characteristics
suggest that binding is accompanied by significant conforma-
tional adjustments (Krogsgaard et al., 2003; Willcox et al.,
1999). Comparison of unliganded (Smith et al., 1998) and com-
plexed structures (herein and Hahn et al., 2005) does indeed
indicate that the peptide andDR2b undergo significant structural
changes on Ob TCR binding (Figure S9 and Figure S11). Similar
adjustments on TCR 3A6 binding to MBP-DR2a have been
suggested to incur an energetic penalty resulting in low affinity
(Li et al., 2005a).
Table 2. Continued
No. of Atoms per Asymmetric Unit (Average B Values, A˚2)
MHC class II (HLA-DR2b) 5 950 (62.4)
Peptide (H. infl ORF 359-373) + 316 (65.0)
linker
abTCR (Ob.1A12) 7 293 (65.3)
Carbohydrates 120 (80.1)
PDB ID 2WBJ
aValues in parentheses correspond to the highest-resolution shell.
bRmerge =
P
J
P
h
ðjIj;h  hIhijÞ=
P
j
P
hðhIhiÞ, in which h is the unique reflec-
tion index, Ij;h is the intensity of the symmetry-related reflection, and hIhi is
the mean intensity.
cR=
P
h
jjFobsjh  jFcalcjhj=
P
h
jFobsjh, in which h defines the unique
reflections.
dRfree calculated over 5.1% of total reflections excluded from refinement.
e Target values in parentheses.
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Our data demonstrate that two different microbial peptides, with
limited sequence homology to MBP, can provoke MS-like
disease in humanized mice by activating the crossreactive MS
patient-derived Ob TCR. One of these peptides is derived from
the essential bacterial GTP-binding protein engA and is strictly
conserved in at least three orders of the Gammaproteobacteriae
class: Aeromonadales, Pasteurellales, and Enterobacteriales.
The Aeromonadales class contains environmental bacteria,
which are normally present in water and soil but are associated
with a variety of clinical presentations, frequently gastroenteritis
(Figueras, 2005). Both the Pasteurellales and Enterobacteriales
classes contain a large number of bacteria, which are either strict
pathogens that always cause disease or part of our normal
(commensal) flora that normally are harmless (Murray et al.,
2002). Nevertheless, it is well recognized that most infections
are caused by commensal bacteria, when they access compart-
Figure 3. Structural Details of Ob TCR
in Complex with E. coli DR2b
(A) Cartoon-representation side view of the Ob
TCR-E.coli DR2b complex. The E. coli peptide is
shown in magenta, the DR2b a-chain in cyan,
the b-chain in green, and the Ob TCR a- and
b-chains in yellow and orange, respectively.
(B) Atomic coloring stick representation of the
E. coli peptide from the Ob TCR-pDR2b complex.
All residues are labeled according to standard
MHC class II presentation nomenclature. The
refined 2Fo-Fc electron density of the peptide resi-
dues to 3 A˚ resolution is contoured at one root
mean square deviation from the mean density.
(C) The same view as panel (B) is shown, with the
MBP peptide (in yellow) from 1YMM.pdb superim-
posed on the E. coli peptide structure (in green),
with their respective amino acid residues labeled
accordingly.
(D) View onto the a, b flanked platform of DR2b
(cartoon representation in gray), with the extended
E. coli peptide in stick representation. Ob TCR
complementarity-determining regions (CDRs) are
represented as coils, with CDR1a in pink, CDR2a
in purple, CDR3a in red, CDR1b in cyan, CDR2b
in green, and CDR3b in blue. The relatively flexible
region of the b-helix of DR2b is highlighted in
yellow.
(E) N-terminal close-up view of the Ob TCR
binding interface, with the E. coli peptide in stick
representation, colored yellow (carbons), red
(oxygens), and blue (nitrogens). Included are:
a partial view of the DR2b helices, in cartoon
representation, and CDR loops as coils (colored
as in panel 3D), with selected interacting residues
in detail. Important hydrogen bonds are repre-
sented with green dashed lines.
ments where they normally do not occur;
e.g., Enterobacteria in the urinary tract
(Murray et al., 2002). This has potential
clinical relevance, given that common
infections have long been implicated in
MS etiology (Marrie, 2004); for example,
by the association between MS relapses and recent infections.
The infections can be either viral or bacterial (Buljevac et al.,
2002; Sibley et al., 1985), but no single MS-associated infectious
agent has been incriminated reproducibly. Possibly, different
infections are involved at different time points in individual
patients and/or the triggering infections vary between patients.
Of relevance in this context is that urinary tract infections,
caused by E. coli, are quite common in women and have been
associated with MS relapses (Correale et al., 2006).
It is thought that onemechanism bywhich infections can stimu-
late autoreactive T cells involves molecular mimicry, in which
a pathogen-derived peptide replicates the TCR binding of a self
antigen in theCNS (Oldstone, 1987), a key question beingwhether
such mimicry results from an inherent degeneracy in the TCR
binding mode, i.e., a promiscuity in possible interactions (Mason,
1998), or reflects a true structural equivalence between the
pMHC surfaces presented for TCR recognition (Lang et al., 2002;
Maynard et al., 2005). Our crystallographic analysis supports theImmunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc. 353
Immunity
Molecular Mimicry in Multiple SclerosisFigure 4. Binding of Ob TCR to Microbial Peptides
(A and B) Ob TCR injections at 200 mM over a surface with immobilised microbial peptide-HLA-DR2b (colored lines), MBP-DR2b (solid black line), or control
peptide-DR2b (dashed line). The response with the control peptide is subtracted for determination of the binding response. Color coding is used as follows:
B. subtilis, green; M. tuberculosis, red; E. coli, purple; and M. avium, cyan.
(C) Measurement of affinity by equilibrium binding analysis. The binding response was determined over a range of Ob TCR concentrations. Kd values were
determined by nonlinear curve fitting of the standard 1:1 binding model to the data.
(D) Scatchard transformations of the same data as in panel (C), in which bound or free TCR is plotted against bound.
(E) Dissociation-phase data after injection of Ob TCR over peptide-DR2b. For aid of comparison, the data are normalized, with response at the start of the
dissociation phase set to 100%. The black lines are first-order exponential fits to the data relating to koff values.
(F) Equilibrium enthalpy change (DH) and heat-capacity change (DCp) accompanying Ob TCRbinding to peptide-DR2bwas determined by van’t Hoff analysis, as
previously described (Lee et al., 2004). Affinities were measured over a range of temperatures, converted to DG, and plotted against temperature. DH, TDS,
and DCp values were derived by fitting of the nonlinear van’t Hoff equation to these data.importance of true structural equivalence, but in a selective form,
namely ‘‘hotspot mimicry.’’ The sequence motif P2-His, P3-Phe
is a strict requirement for Ob TCR binding (Hausmann et al.,
1999; Wucherpfennig et al., 1994). From comparison of the Ob
TCR-E. coli-DR2b and Ob TCR-MBP-DR2b complex structures,
it isclear that thesidechainsof these twopeptide residuesmediate
a set of absolutely conserved interactions at the heart of the TCR-
pMHC interface. Despite numerous interactions between the Ob
TCR and the peptide in both DR2b complexes, the focus of the
interaction is relatively narrow; P2-His and P3-Phe provide a hot-
spot for TCR-peptide binding. In other TCR-pMHC complexes,
interactions contributing to the binding are spread over a greater
number of peptide residues (Rudolph et al., 2006). As previously
noted (Jones et al., 2006; Lang et al., 2002; Li et al., 2005a), the
main chain conformation of peptides presented by MHC class
II molecules is particularly highly conserved for residues P1 to
P5. Thus, the N-terminal-biased binding footprint of the Ob TCR
minimizes indirect contributions to interaction specificity from354 Immunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc.anchor-residue differences influencing main chain conformation.
A second mechanism by which anchor-residue differences may
indirectly have an impact on binding affinity is through changes
in the position of binding-groove helices, but again, the offset
position of the Ob TCRmeans that it does not sample the regions
that show significant changes (Hennecke and Wiley, 2002). The
structure of Ob TCR-MBP-DR2b first raised the possible signifi-
cance of offset position of the TCR in autoimmunity (Hahn et al.,
2005); the structure of 3A6 TCR-MBP-DR2a complex was again
markedly skewed toward the N-terminal half of the peptide
(Li et al., 2005b), and a subsequent structure of a TCR-MHC class
II complex involving an altered self peptide showed a geometry of
binding that was intermediate between that of ‘‘anti-foreign’’ and
that of the two DR2-restricted autoimmune TCRs (Deng et al.,
2007). However, the MHC class II-restricted autoreactive 172.10
TCR docks in a canonical fashion (Maynard et al., 2005), and
therefore, a noncanonical binding geometry cannot be the only
mechanism of autoimmune TCR-pMHC recognition.
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Molecular Mimicry in Multiple SclerosisTable 3. Kinetic and Thermodynamic Parameters of the Interactions of Ob TCR with Peptide-Presenting DR2b at 25C
MBP E.coli M. avium
kon (mol
1.s1) 2280 ± 181 (n = 13) 672 ± 117 (n = 3) 700 ± 48 (n = 3)
koff (s
-1) 0.08 ± 0.005 (n = 13) 0.35 ± 0.005 (n = 3) 0.26 ± 0.005 (n = 3)
Kd calculated (mM) 38 ± 3.7 (n = 13) 565 ± 125 (n = 3) 369 ± 26 (n = 3)
DG (kcal.mol1) a 5.9 ± 0.01 (n = 13) 4.8 ± 0.04 (n = 4) 4.6 ± 0.06 (n = 5)
DH (kcal.mol1) b 6.7 ± 0.7 (n = 2) 21.9 ± 2.8 (n = 2) 20.7
TDS (kcal.mol1) b 0.8 ± 0.7 (n = 2) 17.1 ± 2.7 (n = 2) 16.1
DCp (kcal.mol1.K1) b 1.0 ± 0.1 (n = 2) 1.5 ± 0.4 (n = 2) 2.0
Values are mean ± SEM for nR 3.
aCalculated as DG = RTlnKd, in which Kd is expressed in mol/L.
bDetermined by van’t Hoff analysis (Figure 4F).A number of characteristics of the Ob TCR interaction with
peptide-DR2b render it susceptible to ‘‘hotspot mimicry.’’
However, the total interaction interface does extend beyond
the binding hotspot, and our kinetic studies confirm that struc-
tural differences in the periphery do indeedmodulate the binding
affinity. Given that the structural conservation (mimicry) between
MBP-DR2b and E. coli-DR2b is not perfect for the entire area of
the TCR-binding footprint, it could be viewed that the Ob TCR
shows some degree of degeneracy in its binding. Full degen-
eracy of TCR binding would imply an ability to interface with
two completely dissimilar binding footprints by using unrelated
sets of interactions, the opposite extreme to perfect structural
mimicry. Our analyses reveal that the crossreactivity of the Ob
TCR shows some characteristics of both extremes, which can
be productively combined into the concept of hotspot mimicry.
We see substantial differences in the clinical severity and
neuropathologic changes induced by the MBP, M. avium, and
E. coli peptides. This suggests that different infections may influ-
ence disease to varying degrees via differential stimulation of
autoreactive T cells and thereby contribute to the clinical and
neuropathological heterogeneity that is so characteristic of MS
(Lassmann et al., 2001). It may seem surprising that theM. avium
peptide induced the more severe disease in Ob TCR-DR2b mice
despite the somewhat higher TCR affinity for the E. coli peptide.
However, this difference is small, and the koff, which may be
more important than affinity, is actually slower for the M. avium
peptide. The slightly higher binding affinity of the M. avium
peptide to DR2b (Hausmann et al., 1999) may also contribute
to its somewhat higher disease potency in vivo. Low-affinity
microbial peptides that mimic self antigens would be expected
to be present at a greater frequency than high-affinity peptides.
This might also explain, at least in part, how tolerance might be
overcome by the low-affinity TCR interactions that we report.
Furthermore, when the low-affinity mimicry epitope is presented
in the context of inflammation (or adjuvants), the concomitant
danger signals and costimulation may greatly enhance its immu-
nogenicity (Lang et al., 2005). Even though we have data that
demonstrate that the mimetic engA epitope is processed natu-
rally from whole engA protein and then presented by the DR2b
molecule to stimulate the crossreactive Ob T cells, it remains
to be seen whether natural infections with, e.g., E. coli can also
provoke disease in our humanized mouse model for MS.
Taken altogether, our data suggest that low-affinity hotspot
mimicry (limited to a small number of key aspects of the TCR-binding footprint), rather than high-affinity structural mimicry
(requiring replication of all features of the binding footprint),
may be the more common contributor in the initiation not only
of MS but also of other autoimmune diseases, such as rheuma-
toid arthritis and Type 1 diabetes, in which infections have like-
wise been implicated. Moreover, the same disease-inducing
mimicry peptides can be conserved in many common bacteria,
which might explain why it has been difficult to incriminate indi-
vidual infections in the development of autoimmune diseases.
EXPERIMENTAL PROCEDURES
Generation of TCR Transgenic Mice
Transgenic mice expressing Ob TCR and DR2b were created as previously
reported (Madsen et al., 1999). The live animal experiments were approved
by the Danish Ministry of Justice (Animal Experimentation Inspectorate).
Disease Induction and Clinical Evaluation
Disease was induced by immunizing mice subcutaneously at the base of the
tail with PBS or 250 mg of peptide (Schafer-N) emulsified in an equal volume
of CFA (Sigma-Aldrich) with 0.5 mg mycobacteria/ml. Two hundred nano-
grams of pertussis toxin (Sigma-Aldrich) were injected intravenously at the
time of the immunization, as well as 48 hr later. Disease was scored every
second day for 12 weeks under the following scheme: 0 = no signs of disease;
1 = weak tail or weak waddling gate without loss of tail tone; 2 = hind-limb
weakness or waddling gait with the tail paralyzed; 3 = hind-limb paralysis;
4 = hind-limb paralysis and forelimb weakness; 5 = full paralysis of three or
four legs or premorbid or dead. Animals were sacrificed once they scored 5.
Immunohistochemistry
Mice were deeply anesthetized and perfused intracardially with 4% phos-
phate-buffered paraformaldehyde, and the brains and spinal cords were
removed and embedded in paraffin. Sections of 6 mm thickness were deparaf-
finised with histoclear and rehydrated through a series of graded ethanols.
Endogenous peroxidase was blocked by incubation with 3% hydrogen
peroxide for 30 min, followed by pretreatment with formic acid and/or heated
citrate buffer (pH 6.0). These sections were subsequently incubated with rat or
mouse primary monoclonal antibodies (mAbs). Rat mAbs (anti-Mac3 [BD
PharMingen; 1/25 dilution] for macrophages and anti-CD3, clone MCA1477
[Serotec; 1/100 dilution] for T cells) were diluted in 1.5% normal rabbit serum
and incubated overnight at 4C. Slides were incubated with biotinylated anti-
rat secondary antibody (1/200 dilution) for 1 hr at room temperature, followed
by avidin-biotin-peroxidase complex (ABC Kit, Vector, UK) for 45 min. Mouse
mAbs (against b-amyloid precursor [Zymed], neurofilament 200KD, and
proteolipid protein [Serotec]) were incubated with the sections for 30 min at
room temperature. The M.O.M. (Mouse on Mouse) kit (Vector) was used. In
all cases, visualization was achieved by 3,30-diamino-benzidine tetrahydro-
chloride (DAB) followed by counterstaining with hematoxylin. Sections wereImmunity 30, 348–357, March 20, 2009 ª2009 Elsevier Inc. 355
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mounted in DPX Mountant Medium.
Protein Preparation for Crystallization Purposes
Soluble HLA-DR2b was expressed in Drosophila S2 cells, and HLA-DM were
prepared as described previously (Svendsen et al., 2004; Sloan et al., 1995).
TCR Va and Vb regions were PCR amplified from cDNA derived from the
Ob.1A12 T cell hybridoma and spliced by overlap extension to TCR Ca and
Cb regions, including C-terminal extensions designed to assist the formation
of an interchain disulfide bridge (Stewart-Jones et al., 2003). In the Ob TCR
b chain, the unpaired Cys 13 was replaced by serine. The E. coli peptide
with an octapeptide flexible linker (GGSGGGGG) was attached N terminally
to the b chain construct through primer annealing and ligation. The constructs
were then inserted into the bacterial expression plasmid pET 22b(+) (Novagen)
and expressed and purified as described elsewhere (S.L.H. et al., unpublished
data).
Complex Formation, Crystallization, and Data Collection
Soluble Ob TCR-E. coli peptides were added to DR2b and HLA-DM at a molar
ratio of 6:3:1 and incubated in 20 mM bis Tris pH6.3, 150 mM NaCl at 20C
for 10 hr. The resulting complex was thereafter purified through size exclusion
chromatography (s200 16/60 Amersham Biosciences), concentrated to
12.5 mg/ml, and used in sitting-drop vapor-diffusion setups. Poor-quality
crystals were obtained against equilibration conditions of 0.2 M LiSO4, 0.8 M
K2HPO4, 1.2 M NaH2PO4, 0.1 M CAPS pH 10.5 (Crystal screen Wizard I,
Hampton Research). Crystals were further refined by addition of 1,1,1,3,3,
3-hexafluoro-2-propanol to a final concentration of 8% (Additive Screen,
Hampton Research). A single crystal was vitrified at 100 K after passage
through perfluoropolyether PFO-X125/03 (Lancaster Synthesis). Complete
data to 3.0 A˚ were collected at ID23.2 at the European Synchrotron Radiation
Facility (ESRF) in Grenoble, France. These were processed and scaledwith the
DENZO/SCALEPACK package (Otwinowski and Minor, 1997). The data were
solved through molecular replacement with AMoRe (Navaza, 1994) with the
use of 1YMM.pdb as a model. Each asymmetric unit contained two near-
complete Ob TCR-peptide-DR2b complexes (Figure S12), and the models
were refined to convergence against 95% of the data with REFMAC (Murshu-
dov et al., 1997). Full details of crystallization, data collection, processing, and
refinement can be found in Table 2.
Surface Plasmon Resonance Studies
Ob TCR andDR2b or peptide-DR2bwere expressed and purified as described
elsewhere (S.L.H. et al., unpublished data). Experiments were performed on
a BIAcore 2000 instrument (BIAcore AB) as previously described (Willcox
et al., 1999). Biotinylated pMHC molecules were immobilized to CM5 sensor
chips via covalently coupled streptavidin. Affinity, kinetic, and thermodynamic
constants were determined as previously described (Lee et al., 2004; Wyer
et al., 1999). Experiments at different ligand-immobilization levels (500–4000
response units) showed that kinetic measurements were not significantly
affected by mass transport or rebinding artifacts.
Structure Superposition and Graphical Representations
All superpositions of atomic structures were performed with SHP (Stuart et al.,
1979). All graphical representations of atomic models and density representa-
tions were generated with Pymol (http://www.pymol.org).
SUPPLEMENTAL DATA
Supplemental Data include twelve figures and four tables and can be
found with this article online at http://www.immunity.com/supplemental/
S1074-7613(09)00112-5.
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